Citations

Mayo Clinic

Clear

10814 citation(s) found for "Qi, Robert".

Pleiotropic Contributions of Phospholipase C-γ1 (PLC-γ1) to T-Cell Antigen Receptor-Mediated Signaling: Reconstitution Studies of a PLC-γ1-Deficient Jurkat T-Cell Line
Irvin, Brenda J., Williams, Brandi L., Nilson, A, Maynor, Hannah O., Abraham, Robert T.

Molecular and Cellular Biology | July 27, 2002 | Volume: 20 | Issue: 24 | Pages: 9149-9161

10.1128/mcb.20.24.9149-9161.2000 | PMID 11094067 Get It

Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients
Pescovitz, Mark D., Rabkin, John M. , Merion, Robert M. , Payá, Carlos V., Pirsch, John D., Freeman, Richard B. , O'Grady, John, Robinson, Charles A., To, Zung, Wren, Kristina, Banken, Ludger, Buhles, William, Brown, Frances C., O’Grady, John

Antimicrobial Agents and Chemotherapy | July 27, 2002 | Volume: 44 | Issue: 10 | Pages: 2811-2815

10.1128/aac.44.10.2811-2815.2000 | PMID 10991864 Get It

ABSTRACT The pharmacokinetics of an orally administered valine ester of ganciclovir (GCV), valganciclovir (VGC), were studied. These were compared to the pharmacokinetics of oral and intravenous GCV. Twenty-eight liver transplant recipients received, in an open-label random order with a 3- to 7-day washout, each of the following: 1 g of oral GCV three times a day; 450 mg of VGC per os (p.o.) once a day (q.d.); 900 mg of VGC p.o. q.d.; and 5 mg of intravenous (i.v.) GCV per kg of body weight q.d., given over 1 h. GCV and VGC concentrations were measured in blood over 24 h. One-sided equivalence testing was performed to test for noninferiority of 450 mg of VGC relative to oral GCV (two-sided 90% confidence interval [CI] > 80%) and nonsuperiority of 900 mg of VGC relative to i.v. GCV (two-sided 90% CI < 125%). The exposure of 450 mg of VGC (20.56 μg · h/ml) was found to be noninferior to that of oral GCV (20.15 μg · h/ml; 90% CI for relative bioavailability of 95 to 109%), and the exposure of 900 mg of VGC (42.69 μg · h/ml) was found to be nonsuperior to that of i.v. GCV (47.61 μg · h/ml; 90% CI = 83 to 97%). Oral VGC delivers systemic GCV exposure equivalent to that of standard oral GCV (at 450 mg) or i.v. GCV (at 900 mg of VGC). VGC has promise for effective CMV prophylaxis or treatment with once-daily oral dosing in transplant recipients.
Cell Surface Trafficking of Fas: A Rapid Mechanism of p53-Mediated Apoptosis
Bennett, Martin R. , Macdonald, Kirsty, Chan, Shiu‐Wan , Luzio, J. Paul , Simari, Robert D., Weissberg, Peter L.

Science | July 27, 2002 | Volume: 282 | Issue: 5387 | Pages: 290-293

10.1126/science.282.5387.290 | PMID 9765154 Get It

p53 acts as a tumor suppressor by inducing both growth arrest and apoptosis. p53-induced apoptosis can occur without new RNA synthesis through an unknown mechanism. In human vascular smooth muscle cells, p53 activation transiently increased surface Fas (CD95) expression by transport from the Golgi complex. Golgi disruption blocked both p53-induced surface Fas expression and apoptosis. p53 also induced Fas-FADD binding and transiently sensitized cells to Fas-induced apoptosis. In contrast, lpr and gld fibroblasts were resistant to p53-induced apoptosis. Thus, p53 can mediate apoptosis through Fas transport from cytoplasmic stores.
Papillary Renal Cell Carcinoma: Analysis of Germline Mutations in the MET Proto-Oncogene in a Clinic-Based Population
Lindor, Noralane M. , Dechet, Christopher , Greene, Mark H. , Jenkins, Robert B. , Zincke, M. Tanja, Weaver, Amy L. , Wilson, Marcia, Zincke, Horst, Liu, Wanguo

Genetic Testing | July 26, 2002 | Volume: 5 | Issue: 2 | Pages: 101-106

10.1089/109065701753145547 | PMID 11551094 Get It

Validation of a Simple Histological-Histochemical Cartilage Scoring System
O’Driscoll, Shawn W. , Marx, Robert G. , Beaton, Dorcas , Gallay, Stephen H., Fitzsimmons, James S. , Miura, Yasushi , Fitzsimmons, James S

Tissue Engineering | July 26, 2002 | Volume: 7 | Issue: 3 | Pages: 313-320

10.1089/10763270152044170 | PMID 11429151 Get It

A Tissue-Engineered Stent for Cell-Based Vascular Gene Transfer
Panetta, Carmelo , Miyauchi, Katsumi , Simari, Robert D., Holmes, David R. , Schwartz, Robert S., Caplice, Noel M. , Berry, David

Human Gene Therapy | July 26, 2002 | Volume: 13 | Issue: 3 | Pages: 433-441

10.1089/10430340252792567 | PMID 11860710 Get It

Regulation of ZAP-70 Intracellular Localization: Visualization with the Green Fluorescent Protein
Sloan‐Lancaster, Joanne, Presley, John F. , Williams, Brandi L., Abraham, Robert T. , Lippincott‐Schwartz, Jennifer , Samelson, Lawrence E. , Zhang, Weiguo

The Journal of Experimental Medicine | July 26, 2002 | Volume: 186 | Issue: 10 | Pages: 1713-1724

10.1084/jem.186.10.1713 | PMID 9362531 Get It

To investigate the cellular dynamics of ZAP-70, we have studied the distribution and regulation of its intracellular location using a ZAP-70 green fluorescent protein chimera. Initial experiments in epithelial cells indicated that ZAP-70 is diffusely located throughout the quiescent cell, and accumulates at the plasma membrane upon cellular activation, a phenotype enhanced by the coexpression of Lck and the initiation of ZAP-70 kinase activity. Subsequent studies in T cells confirmed this phenotype. Intriguingly, a large amount of ZAP-70, both chimeric and endogenous, resides in the nucleus of quiescent and activated cells. Nuclear ZAP-70 becomes tyrosine phosphorylated upon stimulation via the T cell receptor, indicating that it may have an important biologic function.
In Vivo Evidence for the Contribution of Human Histocompatibility Leukocyte Antigen (Hla)-Dq Molecules to the Development of Diabetes
Li, Wen , Wong, F. Susan , Chen, Ning-Yuan, Altieri, Martha, David, Chella S., Sherwin, Robert, Tang, Jie , Chen, Ning‐Yuan, Flavell, Richard A.

The Journal of Experimental Medicine | July 26, 2002 | Volume: 191 | Issue: 1 | Pages: 97-104

10.1084/jem.191.1.97 | PMID 10620608 Get It

Although DQA1*0301/DQB1*0302 is the human histocompatibility leukocyte antigen (HLA) class II gene most commonly associated with human type 1 diabetes, direct in vivo experimental evidence for its diabetogenic role is lacking. Therefore, we generated C57BL/6 transgenic mice that bear this molecule and do not express mouse major histocompatibility complex (MHC) class II molecules (DQ8+/mII−). They did not develop insulitis or spontaneous diabetes. However, when DQ8+/mII− mice were bred with C57BL/6 mice expressing costimulatory molecule B7-1 on β cells (which normally do not develop diabetes), 81% of the DQ8+/mII−/B7-1+ mice developed spontaneous diabetes. The diabetes was accompanied by severe insulitis composed of both T cells (CD4+ and CD8+) and B cells. T cells from the diabetic mice secreted large amounts of interferon γ, but not interleukin 4, in response to DQ8+ islets and the putative islet autoantigens, insulin and glutamic acid decarboxylase (GAD). Diabetes could also be adoptively transferred to irradiated nondiabetic DQ8+/mII−/B7-1+ mice. In striking contrast, none of the transgenic mice in which the diabetes protective allele (DQA1*0103/DQB1*0601, DQ6 for short) was substituted for mouse MHC class II molecules but remained for the expression of B7-1 on pancreatic β cells (DQ6+/mII−/B7-1+) developed diabetes. Only 7% of DQ−/mII−/B7-1+ mice developed diabetes at an older age, and none of the DQ−/mII+/B7-1+ mice or DQ8+/mII+/B7-1+ mice developed diabetes. In conclusion, substitution of HLA-DQA1*0301/DQB1*0302, but not HLA-DQA1*0103/DQB1*0601, for murine MHC class II provokes autoimmune diabetes in non–diabetes-prone rat insulin promoter (RIP).B7-1 C57BL/6 mice. Our data provide direct in vivo evidence for the diabetogenic effect of this human MHC class II molecule and a unique “humanized” animal model of spontaneous diabetes.
CD8 T Cells Are Required for the Formation of Ectopic Germinal Centers in Rheumatoid Synovitis
Kang, Young Mo , Zhang, Xiaoyu , Wagner, Ulf , Yang, Hongyu , Beckenbaugh, Robert D., Kurtin, Paul J. , Goronzy, Jörg J. , Weyand, Cornelia M. , Goronzy, Jorg

The Journal of Experimental Medicine | July 26, 2002 | Volume: 195 | Issue: 10 | Pages: 1325-1336

10.1084/jem.20011565 | PMID 12021312 Get It

The assembly of inflammatory lesions in rheumatoid arthritis is highly regulated and typically leads to the formation of lymphoid follicles with germinal center (GC) reactions. We used microdissection of such extranodal follicles to analyze the colonizing T cells. Although the repertoire of follicular T cells was diverse, a subset of T cell receptor (TCR) sequences was detected in multiple independent follicles and not in interfollicular zones, suggesting recognition of a common antigen. Unexpectedly, the majority of shared TCR sequences were from CD8 T cells that were highly enriched in the synovium and present in low numbers in the periphery. To examine their role in extranodal GC reactions, CD8 T cells were depleted in human synovium-SCID mouse chimeras. Depletion of synovial CD8 T cells caused disintegration of the GC-containing follicles. In the absence of CD8 T cells, follicular dendritic cells disappeared, production of lymphotoxin-α1β2 markedly decreased, and immunoglobulin (Ig) secretion ceased. Immunohistochemical studies demonstrated that these CD8 T cells accumulated at the edge of the mantle zone. Besides their unique localization, they were characterized by the production of interferon (IFN)-γ, lack of the pore-forming enzyme perforin, and expression of CD40 ligand. Perifollicular IFN-γ+ CD8 T cells were rare in secondary lymphoid tissues but accounted for the majority of IFN-γ+ cells in synovial infiltrates. We propose that CD8+ T cells regulate the structural integrity and functional activity of GCs in ectopic lymphoid follicles.